Articles

This article presents ideas for regulatory 'safe harbors' under which pharmaceutical companies would be relieved of the responsibility of monitoring social media for adverse events. Includes a detailed summary of responses to the survey 'FDA Regulation of Drug & Device Promotion via the Internet & Social Media' regarding social media adverse event monitoring, processing, challenges, and uncertainties.

Future revenue growth in the US and EU will be limited as the EU wrestles with cost effectiveness and the US debates healthcare reforms. Meanwhile, pharma and biotech companies are looking to emerging market opportunities in Brazil, Russia, India, and China (i.e., BRIC) to drive future business. What does this all mean for patients, physicians, payers, and pharmaceutical/biotech manufacturers? This article addresses that question.

Risk management, REMS, danger management of your product's life cycle, whatever you call it, all are crucial to brand managers and marketing executives. This article summarizes Fetterman's ideas about how to develop a REMS that can be a win-win-win situation for you, your product, and the patient.

Welcome to the September 2009 issue of Pharma Marketing News.

Welcome to the September 2009 issue of Pharma Marketing News.

What If There Were No Rules in Pharma Marketing? There's no FDA, no DDMAC, no FTC. Your company guidelines and rules don't exist and your regulatory and legal teams have been disbanded. It's a free-for-all and there are no rules. The question is: what would you do?

Pharma Marketing News surveyed readers to determine if medical journal articles sponsored and ghostwritten by drug companies are a legitimate part of marketing to physicians and to get opinions on various other issues raised in the press about ghostwriting.

No matter what people say, your Twitter strategy must include building a large and qualified Twitter following. This article summarizes the findings of a survey of over 400 of @pharmaguy's followers. The results will give you a better idea why people who are interested in the pharmaceutical industry use Twitter and what they expect to get out of it.

The security of a controlled environment for pharma marketing communication is giving way to the complexities of a dynamic environment with more empowered players, including patients who have more influence than ever before over which products make it to market and which are prescribed. Brand managers need to observe, gauge and seek to influence those influencers. Therefore, we need a new model that helps us make sense of a complex world of communications. This article presents such a model developed by TNS Healthcare, A Kantar Health Company.

An excellent gauge of the state of social communications in healthcare may be had from summaries of the roundtable discussions at the Social Communications in Healthcare conference hosted by the Business Development Institute in NYC on July 23, 2009. This article provides several summaries written by the roundtable discussion leaders themselves.